CLINUVEL expands Singapore laboratory facilities
Analytical capability established for follow-on innovative product lines at VALLAURIX, a fully owned subsidiary
• VALLAURIX laboratory expansion, addition of critical analytical methodologies
• Supply chain integration as part of CLINUVEL’s commercial objectives
• VALLAURIX focus on development of CUV9900, VLRX001 and OTC products
• Laboratory research on topical and paediatric formulation
Melbourne, Australia and Singapore, 29 October 2018
CLINUVEL PHARMACEUTICALS LTD today announced that its fully owned Singaporean subsidiary VALLAURIX PTE LTD is expanding its laboratory facilities to incorporate a variety of critical analytical functions. As part of the increase in research activities on next generation products, new analytical capacity is being added and will be integrated into the newly built premises.
CLINUVEL established its first experimental laboratory in Singapore in 2014 to accelerate drug discovery and development. As the next stage of the Group’s development plan and part of its commercial objectives, CLINUVEL aims to achieve supply chain integration of critical analytical functions.
In the initial stage experimental work was performed in the domains of physics and optics to further investigate the interaction of light and human biology (skin). In the drug discovery stage, a number of drug candidates had been identified, of which the new chemical entities (NCEs) CUV9900 and VLRX001 were selected to advance to clinical products in various formulations.
VALLAURIX is focussed on the development of topical formulations for transdermal administration of the novel products, both as pharmaceutical product lines and non-prescription over-the-counter-products. In addition, the scientific team is progressing the development of a paediatric formulation of SCENESSE® (afamelanotide 16mg) as outlined in the Paediatric Investigation Plan overseen by the European Medicines Agency.1
With the expansion of its analytical capabilities the VALLAURIX team is equipped to employ a variety of analytical methodologies in-house to support new product development, as well as quality control functions.
“Investments in further analytical capabilities is, from CLINUVEL’s perspective, mandatory since validated analytical methodologies are needed to strengthen our intellectual property and knowhow on innovative products,” CLINUVEL’s Chief Scientific Officer, Dr Dennis Wright said. “The choice to either outsource many of these pivotal functions or establish a fully integrated company was made a long time ago to ensure we own all the components of the novel technology prior to commercial launch, and that includes analytical methodologies.”
“Singapore, as a leading economy and innovative nation, provides us with an excellent opportunity to develop and grow thanks in part to the calibre and drive of its workforce. CLINUVEL strives to become the prime company to develop a molecule from laboratory to market out of this country, very much in following our business approach to date. With the expertise and template laid down by the work we have done for patients with the innovative drug SCENESSE®, we expect the new molecules to go through the regulatory pathway much faster. Our immediate aim is for CUV9900 to be available for use in the clinic,” Dr Wright said.1
– End –
1 SCENESSE® (afamelanotide16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity in adult patients with EPP. Information on the product can be found on CLINUVEL’s website at www.clinuvel.com.
About CLINUVEL PHARMACEUTICALS LIMITED
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore, with the UK acting as the EU distribution centre.
For more information go to http://www.clinuvel.com.
SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.
USA: Terri Clevenger, Continuum Health Communications, T +1 (203) 227-0209, firstname.lastname@example.org
Europe: Lachlan Hay, CLINUVEL (UK) LTD, T +44 1372 860 765, Lachlan.Hay@clinuvel.com
This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause CLINUVEL’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that CLINUVEL may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs.
Level 6, 15 Queen Street
Melbourne, Victoria 3000
T +61 3 9660 4900
F +61 3 9660 4999